BGG is pleased to announce that it has successfully completed the registration of Enoxolone (EC: 207-444-6, CAS: 471-53-4) in accordance with the REACH regulation (EC) No 1907/2006.
As lead registrant, BGG has collected all data, developed the technical dossier and Chemical Safety Report (CSR) and managed the submission of registration dossier to ECHA. “18-beta Glycyrrhetinic Acid is of strategic importance to our company. This registration is a mandatory regulatory requirement to be able to continue to serve our European customers, and no other lead registrant or REACH consortium was in place” said Christian Artaria, CEO of BGG Europe SA. “For this reason, we had to complete all regulatory tasks by ourselves.” The licorice derivatives market has been characterized for many years by very few suppliers controlling the entire production chain, with many other companies trading or simply claiming to produce these ingredients.